RxDoctor Payments DataLook up a doctor →

Collins Liu, MD

Behavioral Neurology & Neuropsychiatry · San Diego, CANPI 1851547459

Payments from drug & device makers

$847,780in general payments, 2019–2025

Across 215 payments — averaging $3943.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Eli Lilly$819K
  • Eisai Inc.$15K
  • Biogen$10K
  • Lilly USA, LLC$600
  • AbbVie$574
  • Teva Pharmaceuticals USA, Inc.$447
  • plus $2K from 27 others
$86,559in research payments, 2019–2025

Across 7 payments — averaging $12,366 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Eli Lilly$87K

What the payments were for

  • Consulting fees$28,86177%
  • Speaking & faculty fees$1,6955%
  • Travel & lodging$2,5337%
  • Food & beverage$4,35012%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few behavioral neurology & neuropsychiatry providers in Californiato place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$120,069
Medicare patients
204
Services billed
1,366

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Nurtec OdtRimegepant Sulfate19$29,407
QuliptaAtogepant12$15,702
RivastigmineRivastigmine Tartrate85$4,309
Rivastigmine17$4,011
Memantine Hcl ErMemantine Hcl11$1,903
Memantine Hcl73$1,793
Donepezil Hcl158$1,323
Levetiracetam20$748
Oxcarbazepine12$642
Escitalopram Oxalate41$558
Quetiapine Fumarate29$474
Gabapentin65$463
Trazodone Hcl76$400
Galantamine Hbr11$356
Duloxetine Hcl14$239

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerNurtec Odt$46$29,40719 claims
AbbVieQulipta$574$15,70212 claims
Almatica Pharma LLCSertraline Hcl$17$3314 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few behavioral neurology & neuropsychiatry providers in Californiaon file to place this against a meaningful peer group, so we don't.

Other behavioral neurology & neuropsychiatry in San Diego

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →